Bi/ond and collaboration generates 3D in vitro model for studying Duchenne Muscular Dystrophy (DMD)

DMD collaboration

By creating a functional 3D in vitro model using cells with a DMD-causing mutation, this Bi/ond and collaboration offers a significant advancement for DMD research and drug discovery

Delft, the Netherlands, 07:30 CEST and Cambridge, UK 06:30 BST, 30th April 2024 – Bi/ond, a TechBio company empowering pharmaceutical companies to make drug decisions through the fusion of hardware, machine learning, and tissue engineering, and, the company coding human cells for novel cures, today announced the generation of a 3D in vitro model for studying Duchenne Muscular Dystrophy (DMD), stemming from their collaboration. 


DMD is a genetic disorder causing progressive muscle degeneration and weakness, primarily affecting males, with an incidence of 6 out of 100,000 individuals*. Symptoms of muscle weakness emerge in early childhood. Despite much effort, there are no curative therapies for DMD. Research using 3D in vitro models has the potential to help accelerate the discovery of much-need treatments. 


Bi/ond has established protocols to generate and characterize human 3D skeletal muscle microtissues within its MUSbit platform using opti-ox™ powered, defined and functional iPSC-derived ioSkeletal Myocytes™ and associated DMD disease model cells from The disease models carry a genetically engineered hemizygous deletion in exon 44 or exon 52 of the DMD gene encoding the dystrophin protein, and were compared to their genetically matched healthy control. 

Duchenne 3D in vitro model

"We are delighted that this collaboration with Bi/ond has led to the creation of a human 3D in vitro model to study how exon deletions impact muscle cell function with’s DMD disease model cells. Our cells offer consistency, scalability and reproducibility, overcoming the challenges associated with the use of alternatives such as primary muscle cells, immortalised cell lines and animal models, which suffer from variability and may not accurately represent human biology. Having access to a physiologically relevant translational model for DMD will help scientists accelerate the development of treatments for this relentlessly progressive degenerative disease

Bi/ond’s scientists successfully assessed cells for myotube formation and 3D tissue self-organization and evaluated contractile responses to various electrical stimuli. Within a week, they reliably generated functional 3D muscle bundles with striated myotubes and established protocols for recording intracellular calcium transients. 

The result shows replication of key aspects of DMD pathophysiology in a human 3D in vitro model. 

This achievement was made possible through the combined expertise of the partners and Bi/ond’s silicon-based technology, which integrates tissue growth, drug testing, and activity recording on a single platform, optimizing experimentation while reducing cell usage. 

“The promising outcomes of our DMD cell experiments, conducted in collaboration with, emphasize the transformative potential of joint research efforts in addressing critical, unmet medical needs such as Duchenne Muscular Dystrophy. These results showcase the capabilities of Bi/ond, facilitating the growth, tracking, and testing of 3D tissues on a single platform equipped with high-throughput, microfluidics, and sensing capabilities. This innovative approach enables the generation of human-like data, thanks to the integration of advanced microelectronics”.

Cinzia Silvestri, CEO and founder Bi/ond, the startup where biology meets engineering

The model and protocols developed are now accessible. Companies in the DMD spectrum striving for innovative treatments are encouraged to reach out to Bi/ond for detailed insights and possibilities. 

For further information contact: 
Bi/ond – –

Media Enquiries 
Bi/ond – Zuriñe Garcia – – Chris Hempel, Spark Public Relations,

If you are interested in the results obtained or want to schedule a demo, get in contact now 

About Bi/ond 
Bi/ond is a biotechnology company at the forefront of drug discovery. We leverage our unique expertise in combining hardware, machine learning, and tissue engineering to empower pharmaceutical companies to make informed drug development decisions. 

At the heart of our technology lies a groundbreaking silicon chip, seamlessly integrating sensors, living 3D human tissues, and a blood vessel, thus creating an environment mirroring the human body. This technology enables the generation of reliable, human-relevant data for drug testing, accelerating the journey towards life-saving treatments. 

Follow us on LinkedIn: 

About is a synthetic biology company focused on human cells that is advancing medicine and enabling curative treatments.’s opti-ox™ precision cell programming and manufacturing technology enables conversion of induced pluripotent stem cells into any desired human cell type in a single step. This can be achieved within days and at industrial scale, while maintaining exceptional purity and unparalleled consistency.’s cell therapy pipeline, based on txCells™, is focused on serious diseases that lack effective treatments. Our lead candidate, bbHEP01 based on txHepatocytes, is in development as a treatment for patients suffering from acute liver failure (ALF) and acute-on-chronic liver failure (ACLF). Our extensive ioCells™ research cell product portfolio is opening up new possibilities for studying human biology and developing new medicines. The company was spun out of the University of Cambridge in 2016 and has raised approximately $200m.

*source : Muscular Dystrophy Association

On Demand Webinar: Advancements in 3D modeling – Building mature, functional 3D skeletal muscle microtissues in vitro

Webinar recording now available - Skeletal muscle

If you missed the live session, or want to go back to some of the key aspects of the webinar, you can access now on demand!! 

Watch this webinar if you want to:

  • Discover how to culture 3D muscle cell bundles on Bi/ond’s MUSbit platform
  • Learn how to combine Bi/ond’s technology with ioSkeletal Myocites (and other skeletal muscle cells) for measuring muscle contractions triggered by electrical stimulation.
  • Explore the translational potential of the MUSbit/Let-it-bit for pharmacological studies on wild-type and disease model cells. 

WEBINAR : Advancements in 3D modelling: Building mature, functional 3D skeletal muscle microtissues in vitro

Webinar advances in 3D modelling , 13 October 2023

Join us for an inspiring session where we present to you how we have  successfully cultured’s human iPSC-derived ioSkeletal Myocytes™ on Bi/ond’s perfusable Organ-on-Chip platform, generating 3D skeletal muscle microtissues. 

In this webinar, you will learn how you can reliably generate functional 3D muscle bundles containing striated multinucleated myocytes in less than a week. 

Find out how to pace and train your muscle tissue simulating physiological conditions, achieve accelerated muscle maturation and enhanced contractile response. 

Discover how Bi/ond’s chip technology can unlock the possibilities of your research to study vascularization, dynamic drug response, and even mimic the immune system’s response. 

Key learning objectives

  • Discover how to culture 3D muscle cell bundles on Bi/ond’s MUSbit™ platform
  • Learn how to combine Bi/ond’s technology with ioSkeletal Myocytes for measuring muscle contractions triggered by electrical stimulation
  • Explore the translational potential of the MUSbit/Let-it-bit™ for pharmacological studies on wild-type and disease model cells

PRESENTATION : Stimulating 3D Skeletal Muscle Microtissues in a Novel Perfusable Microphysiological System with Integrated Electrodes

IIm meeting talk Skeletal Muscle culture


Stimulating Skeletal Muscle Microtissues in a novel perfusable mucrophysiological system integrated with electrodes. This is the title of the presentation that our CTO, Nikolas Gaio, will be giving in Italy soon. The meeting of the Interuniversity Institute of Miology, is taking place in Assisi Italy, 12-15 of October.

During the session, Nikolas will talk to the audience about how Bi/ond has managed to stimulate 3D Skeletal Muscle Microtissues in our perfusable microphysiological system, incorporating integrated electrodes.

He will present the results of our assay where we successfully culture skeletal muscle cells on our MUSbit™ platform, obtaining as a result 3D muscle bundles, and experiencing robust muscle contraction.

Do not miss this opportunity to see this ground breaking results in first person!

To get you in the mood for it, you can always visit our website to discover this and other applications for your research :

To attend: